pentoxifylline has been researched along with Cirrhosis, Liver in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentoxifylline is effective in preventing HRS in patients with cirrhosis and ascites at risk of HRS." | 9.15 | Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. ( Kumar, A; Puri, AS; Sarin, SK; Sharma, BC; Sharma, P; Tyagi, P, 2011) |
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 7.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| "Treatment with pentoxifylline did not improve arterial oxygenation in advanced HPS, and tolerance was limited by gastrointestinal toxicity." | 6.73 | Pilot study of pentoxifylline in hepatopulmonary syndrome. ( Fallon, MB; Faulk, DK; Kawut, SM; Philips, GM; Tanikella, R, 2008) |
| "5 times) were given pentoxyfylline at a dosage of 400 mg t." | 6.73 | Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. ( Malhotra, V; Sakhuja, P; Sarin, SK; Satapathy, SK; Sharma, BC, 2007) |
| "DS and PTX could mitigate liver cirrhosis through modulation of Keap-1/Nrf-2/GSH and NF-κB-p65/p38-MAPK signaling pathways." | 5.48 | Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis. ( Abo-Youssef, AM; Ali, FEM; Azouz, AA; Bakr, AG; Hemeida, RAM, 2018) |
| "Pentoxifylline is effective in preventing HRS in patients with cirrhosis and ascites at risk of HRS." | 5.15 | Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. ( Kumar, A; Puri, AS; Sarin, SK; Sharma, BC; Sharma, P; Tyagi, P, 2011) |
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 3.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| " To investigate the potential role of fetuin and pentoxifylline in fibrosis we used MCM samples obtained from patients with biopsy proven hepatic fibrosis related to Hepatitis C (HCV)." | 3.74 | Effect of fetuin, a TGFbeta antagonist and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and fibrotic parameters in fibrosis. ( Peterson, MR; Peterson, TC; Verma-Gandhu, M, 2007) |
| "Treatment with pentoxifylline was the only factor associated with liver-related complications." | 2.75 | Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. ( Barraud, H; Carbonell, N; Condat, B; Lebrec, D; Moreau, R; Oberti, F; Perarnau, JM; Poynard, T; Ramond, MJ; Renard, P; Saliba, F; Thabut, D, 2010) |
| "Treatment with pentoxifylline did not improve arterial oxygenation in advanced HPS, and tolerance was limited by gastrointestinal toxicity." | 2.73 | Pilot study of pentoxifylline in hepatopulmonary syndrome. ( Fallon, MB; Faulk, DK; Kawut, SM; Philips, GM; Tanikella, R, 2008) |
| "5 times) were given pentoxyfylline at a dosage of 400 mg t." | 2.73 | Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. ( Malhotra, V; Sakhuja, P; Sarin, SK; Satapathy, SK; Sharma, BC, 2007) |
| "However, most patients with NAFLD/NASH will die from a vascular cause." | 2.72 | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. ( Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A, 2021) |
| " Either a low uptake of the compounds in the cells that cause disease might account for this lack of effect, or side-effects in other cells may limit the dosage of the drugs." | 2.41 | Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. ( Beljaars, L; Meijer, DK; Poelstra, K, 2002) |
| "Animals without steatosis (ie NAFLD) at week 16 were excluded from the data analysis." | 1.62 | The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis. ( Andersen, M; Buelund, LE; Ipsen, DH; Latta, M; Lintrup, K; Lykkesfeldt, J; Skaarup, R; Skat-Rørdam, J; Svenningsen, M; Tveden-Nyborg, P, 2021) |
| "DS and PTX could mitigate liver cirrhosis through modulation of Keap-1/Nrf-2/GSH and NF-κB-p65/p38-MAPK signaling pathways." | 1.48 | Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis. ( Abo-Youssef, AM; Ali, FEM; Azouz, AA; Bakr, AG; Hemeida, RAM, 2018) |
| "Pentoxifylline (PTX), which is a xanthine derivative, is a well-known suppressor of tumor necrosis factor-alpha (TNF-alpha) production in inflammatory cells and has also been shown to inhibit collagen synthesis in hepatic stellate cells (HSCs) in vitro." | 1.38 | Pentoxifylline inhibits hepatic stellate cells proliferation via the Raf/ERK pathway. ( Jiang, H; Ma, J; Wang, Y; Zhang, D, 2012) |
| "Acetaldehyde-treated cells pretreated with an anti-IL-6 monoclonal antibody did not show any increase in alpha (I) collagen expression." | 1.35 | Pentoxifylline downregulates alpha (I) collagen expression by the inhibition of Ikappabalpha degradation in liver stellate cells. ( Bucio, L; Escobar, MC; Farfán, B; Gómez-Quiroz, LE; Gutiérrez-Ruiz, MC; Hernández, E; Kershenobich, D; Souza, V, 2008) |
| "Effects of PTX on the content change of hepatic TGF-beta1, type I and type III collagen in schistosomiasis japonica mice with liver fibrosis were related to the dosage of PTX, high dose PTX treated group could significantly reduce the content of TGF-beta1 (0." | 1.32 | Effects of pentoxifylline on the hepatic content of TGF-beta1 and collagen in Schistosomiasis japonica mice with liver fibrosis. ( Cai, SQ; Luo, DD; Xiong, LJ; Zen, LL; Zhu, JF, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 4 (12.12) | 18.2507 |
| 2000's | 15 (45.45) | 29.6817 |
| 2010's | 11 (33.33) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Mahjoubin-Tehran, M | 1 |
| De Vincentis, A | 1 |
| Mikhailidis, DP | 1 |
| Atkin, SL | 1 |
| Mantzoros, CS | 1 |
| Jamialahmadi, T | 1 |
| Sahebkar, A | 1 |
| Ipsen, DH | 1 |
| Skat-Rørdam, J | 1 |
| Svenningsen, M | 1 |
| Andersen, M | 1 |
| Latta, M | 1 |
| Buelund, LE | 1 |
| Lintrup, K | 1 |
| Skaarup, R | 1 |
| Lykkesfeldt, J | 1 |
| Tveden-Nyborg, P | 1 |
| Stine, JG | 1 |
| Wang, J | 1 |
| Cornella, SL | 1 |
| Behm, BW | 1 |
| Henry, Z | 1 |
| Shah, NL | 1 |
| Caldwell, SH | 1 |
| Northup, PG | 1 |
| Ali, FEM | 1 |
| Bakr, AG | 1 |
| Abo-Youssef, AM | 1 |
| Azouz, AA | 1 |
| Hemeida, RAM | 1 |
| Metwally, AH | 1 |
| Khalifa, EA | 1 |
| Nemenqani, DM | 1 |
| Li, H | 1 |
| Hua, J | 1 |
| Guo, CX | 1 |
| Wang, WX | 1 |
| Wang, BJ | 1 |
| Yang, DL | 1 |
| Wei, P | 1 |
| Lu, YP | 1 |
| Tanikella, R | 1 |
| Philips, GM | 1 |
| Faulk, DK | 1 |
| Kawut, SM | 1 |
| Fallon, MB | 1 |
| Lebrec, D | 2 |
| Thabut, D | 1 |
| Oberti, F | 1 |
| Perarnau, JM | 1 |
| Condat, B | 1 |
| Barraud, H | 1 |
| Saliba, F | 1 |
| Carbonell, N | 1 |
| Renard, P | 1 |
| Ramond, MJ | 1 |
| Moreau, R | 1 |
| Poynard, T | 1 |
| Kendrick, SF | 1 |
| Day, CP | 1 |
| Tyagi, P | 1 |
| Sharma, P | 1 |
| Sharma, BC | 2 |
| Puri, AS | 1 |
| Kumar, A | 1 |
| Sarin, SK | 2 |
| Corradi, F | 1 |
| Brusasco, C | 1 |
| Fernández, J | 1 |
| Vila, J | 1 |
| Ramirez, MJ | 1 |
| Seva-Pereira, T | 1 |
| Fernández-Varo, G | 1 |
| Mosbah, IB | 1 |
| Acevedo, J | 1 |
| Silva, A | 1 |
| Rocco, PR | 1 |
| Pelosi, P | 1 |
| Gines, P | 1 |
| Navasa, M | 1 |
| Hemsworth-Peterson, TC | 1 |
| Zhang, D | 1 |
| Jiang, H | 1 |
| Wang, Y | 1 |
| Ma, J | 1 |
| Xiong, LJ | 1 |
| Zhu, JF | 1 |
| Luo, DD | 1 |
| Zen, LL | 1 |
| Cai, SQ | 1 |
| Tarçin, O | 2 |
| Avşar, K | 1 |
| Demirtürk, L | 1 |
| Gültepe, M | 1 |
| Oktar, BK | 1 |
| Ozdoğan, OC | 1 |
| Baloğlu, H | 1 |
| Gürbüz, AK | 1 |
| Sztrymf, B | 1 |
| Rabiller, A | 1 |
| Nunes, H | 1 |
| Savale, L | 1 |
| Le Pape, A | 1 |
| de Montpreville, V | 1 |
| Mazmanian, M | 1 |
| Humbert, M | 1 |
| Hervé, P | 1 |
| Gonzalo, T | 1 |
| Talman, EG | 1 |
| van de Ven, A | 1 |
| Temming, K | 1 |
| Greupink, R | 1 |
| Beljaars, L | 2 |
| Reker-Smit, C | 1 |
| Meijer, DK | 4 |
| Molema, G | 1 |
| Poelstra, K | 2 |
| Kok, RJ | 1 |
| van de Bovenkamp, M | 2 |
| Groothuis, GM | 2 |
| Olinga, P | 2 |
| Chitturi, S | 1 |
| Farrell, GC | 1 |
| Satapathy, SK | 1 |
| Sakhuja, P | 1 |
| Malhotra, V | 1 |
| Verma-Gandhu, M | 1 |
| Peterson, MR | 1 |
| Peterson, TC | 1 |
| Hernández, E | 1 |
| Bucio, L | 1 |
| Souza, V | 1 |
| Escobar, MC | 1 |
| Gómez-Quiroz, LE | 1 |
| Farfán, B | 1 |
| Kershenobich, D | 1 |
| Gutiérrez-Ruiz, MC | 1 |
| Paradowski, PT | 1 |
| Zeman, K | 1 |
| Pinzani, M | 1 |
| Marra, F | 1 |
| Caligiuri, A | 1 |
| DeFranco, R | 1 |
| Gentilini, A | 1 |
| Failli, P | 1 |
| Gentilini, P | 1 |
| Windmeier, C | 1 |
| Gressner, AM | 1 |
| Préaux, AM | 1 |
| Mallat, A | 1 |
| Rosenbaum, J | 1 |
| Zafrani, ES | 1 |
| Mavier, P | 1 |
| de Souza, MM | 1 |
| Silva, LM | 1 |
| Barbosa, AA | 1 |
| de Oliveira , IR | 1 |
| Paraná, R | 1 |
| Andrade, ZA | 1 |
| Reis, LF | 1 |
| Ventura, TG | 1 |
| Souza, SO | 1 |
| Arana-Pino, A | 1 |
| Pelajo-Machado, M | 1 |
| Pereira, MJ | 1 |
| Lenzi, HL | 1 |
| Conceição, MJ | 1 |
| Takiya, CM | 1 |
| Koczorek, M | 1 |
| Koppenhagen, K | 1 |
| Wenig, HG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Single Arm Pilot Study of Pentoxifylline in Advanced Hepatopulmonary Syndrome[NCT00593658] | Phase 1 | 9 participants (Actual) | Interventional | 2004-06-30 | Terminated (stopped due to Poor tolerability of drug and side effects) | ||
| Clinical Trial of Pentoxifylline Administration Versus Placebo on Survival in Patients With Cirrhosis and Severe Liver Failure[NCT00162552] | Phase 3 | 342 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| Pentoxifylline Dose Optimization in Preterm Neonatal Late Onset Sepsis[NCT04152980] | Phase 3 | 40 participants (Anticipated) | Interventional | 2020-01-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
4 reviews available for pentoxifylline and Cirrhosis, Liver
| Article | Year |
|---|---|
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Di | 2021 |
[Pentoxifylline].
Topics: Acquired Immunodeficiency Syndrome; Animals; Autoimmune Diseases; Humans; Immunity, Cellular; Killer | 1995 |
Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis.
Topics: Animals; Humans; Liver Cirrhosis; Pentoxifylline; Vasodilator Agents | 1997 |
Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis.
Topics: Animals; Cytokines; Drug Delivery Systems; Genetic Therapy; Gliotoxin; Humans; Liver; Liver Cirrhosi | 2002 |
6 trials available for pentoxifylline and Cirrhosis, Liver
| Article | Year |
|---|---|
Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial.
Topics: Aged; Albumins; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Hospital Mortality; Humans; | 2018 |
Pilot study of pentoxifylline in hepatopulmonary syndrome.
Topics: Aged; Blood Gas Analysis; Female; Hepatopulmonary Syndrome; Humans; Liver Cirrhosis; Male; Middle Ag | 2008 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; France; Gastrointestin | 2010 |
Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo.
Topics: Adult; Ascites; Creatinine; Female; Hepatorenal Syndrome; Humans; Kidney Function Tests; Liver Cirrh | 2011 |
Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
Topics: Administration, Oral; Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; | 2007 |
[The effect of pentoxifylline on liver perfusion: a comparative study in patients with liver diseases and in normal subjects, using 198Au-colloid-scintigraphy (author's transl)].
Topics: Adult; Aged; Chronic Disease; Female; Hepatitis; Humans; Liver; Liver Circulation; Liver Cirrhosis; | 1979 |
23 other studies available for pentoxifylline and Cirrhosis, Liver
| Article | Year |
|---|---|
The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis.
Topics: Animals; Aspirin; Diet, High-Fat; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Reposit | 2021 |
Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis.
Topics: Animals; Cytoglobin; Diosmin; Disease Progression; Free Radicals; Gene Expression Profiling; Globins | 2018 |
Pentoxifylline in the management of metabolic syndrome and chronic hepatitis C.
Topics: Antiviral Agents; Cardiovascular Diseases; Hepatitis C, Chronic; Humans; Insulin Resistance; Liver C | 2014 |
Efficacy of pentoxifylline as an antifibrotic drug in experimental murine schistosomal hepatic fibrosis.
Topics: Animals; Female; Free Radical Scavengers; Leptin; Liver Cirrhosis; Male; Mice; Pentoxifylline; Schis | 2014 |
Pentoxifylline inhibits liver fibrosis via hedgehog signaling pathway.
Topics: Animals; Antigens, Helminth; Cell Culture Techniques; Cell Differentiation; Cell Line; Culture Media | 2016 |
Liver: Can pentoxifylline secure its place in liver therapeutics?
Topics: Humans; Liver Cirrhosis; Palliative Care; Pentoxifylline; Vasodilator Agents | 2010 |
Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Translocatio | 2012 |
The mechanism behind the novel fibrosis recently described in NASH in HEPATOLOGY 2011 and elsewhere.
Topics: Cohort Studies; Fatty Liver; Female; Forecasting; Gastroenterology; Hepatitis C, Chronic; Humans; Li | 2012 |
Pentoxifylline inhibits hepatic stellate cells proliferation via the Raf/ERK pathway.
Topics: Animals; Apoptosis; Butadienes; Cell Line; Cell Proliferation; Extracellular Signal-Regulated MAP Ki | 2012 |
Effects of pentoxifylline on the hepatic content of TGF-beta1 and collagen in Schistosomiasis japonica mice with liver fibrosis.
Topics: Animals; Anthelmintics; Collagen Type I; Collagen Type III; Female; Liver; Liver Cirrhosis; Mice; Pe | 2003 |
In vivo inefficiency of pentoxifylline and interferon-alpha on hepatic fibrosis in biliary-obstructed rats: assessment by tissue collagen content and prolidase activity.
Topics: Animals; Cholestasis; Collagen; Dipeptidases; Disease Models, Animal; Drug Therapy, Combination; Fem | 2003 |
Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats.
Topics: Animals; Aorta; Bacterial Translocation; Blood Cells; Blood Circulation; Enzyme Inhibitors; Hemodyna | 2004 |
Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology.
Topics: Actins; Animals; Biological Availability; Caspase 3; Caspases; Cell Survival; Chemistry, Pharmaceuti | 2006 |
Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro.
Topics: Actins; Animals; Benzamides; Biomarkers; Collagen; Collagen Type I; Collagen Type I, alpha 1 Chain; | 2006 |
TNF-alpha as therapeutic target in NASH: tried, but not yet proven.
Topics: Animals; Fatty Liver; Hepatitis; Humans; Liver; Liver Cirrhosis; Necrosis; Pentoxifylline; Protectiv | 2007 |
Effect of fetuin, a TGFbeta antagonist and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and fibrotic parameters in fibrosis.
Topics: Aldehydes; alpha-Fetoproteins; Animals; Apoptosis; Cell Differentiation; Cells, Cultured; Collagen; | 2007 |
Pentoxifylline downregulates alpha (I) collagen expression by the inhibition of Ikappabalpha degradation in liver stellate cells.
Topics: Acetaldehyde; Animals; Antibodies, Monoclonal; Blotting, Western; Cell Line; Collagen Type I; Electr | 2008 |
Liver slices as a model to study fibrogenesis and test the effects of anti-fibrotic drugs on fibrogenic cells in human liver.
Topics: Adolescent; Adult; Aged; Carbon Tetrachloride Poisoning; Cell Shape; Cell Survival; Child; Child, Pr | 2008 |
Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells.
Topics: Adipocytes; Calcium; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cells, Cultured; D | 1996 |
Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells.
Topics: Cell Division; Cells, Cultured; Collagen; Gelatinases; Humans; Liver; Liver Cirrhosis; Matrix Metall | 1997 |
Hepatic capillariasis in rats: a new model for testing antifibrotic drugs.
Topics: Animals; Capillaria; Disease Models, Animal; Enoplida Infections; Female; Gadolinium; Liver Cirrhosi | 2000 |
Quantitative and qualitative interferences of pentoxifillyne on hepatic Schistosoma mansoni granulomas: effects on extracellular matrix and eosinophil population.
Topics: Animals; Collagen; Eosinophils; Extracellular Matrix; Granuloma; Liver Cirrhosis; Liver Diseases, Pa | 2001 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; | 2001 |